Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma

Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC

ASCO 2026: Lung cancer roundup

Sacituzumab govitecan plus pembrolizumab improves outcomes beyond progression in PD-L1-positive mTNBC

Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk melanoma

Tarlatamab in SCLC shows consistent effect and low immune toxicity across age groups

Adjuvant avelumab reduces relapse risk in stage III Merkel cell carcinoma

Olaparib plus pembrolizumab improves response but not PFS in BRCA-mutant pancreatic cancer

Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma

ASCO 2026: Latest updates in mRCC

Tafasitamab plus lenalidomide and R-CHOP delays disease progression in aggressive B-cell lymphomas

Adagloxad simolenin plus OBI-821 shows no survival benefit compared to standard of care in triple-negative breast cancer